监测移植后作为微小残留病的CBFB-MYH11，而非KIT突变，可预测成人inv(16)急性髓系白血病异基因造血细胞移植后的复发。 - Suppr

Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.

作者信息

Tang Fei-Fei, Xu Lan-Ping, Zhang Xiao-Hui, Chen Huan, Chen Yu-Hong, Han Wei, Wang Yu, Yan Chen-Hua, Sun Yu-Qian, Mo Xiao-Dong, Liu Kai-Yan, Huang Xiao-Jun

机构信息

Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.

Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.

出版信息

Br J Haematol. 2018 Feb;180(3):448-451. doi: 10.1111/bjh.14340. Epub 2016 Sep 21.

DOI:10.1111/bjh.14340

PMID:27650511

Abstract

摘要

相似文献

Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.监测移植后作为微小残留病的CBFB-MYH11，而非KIT突变，可预测成人inv(16)急性髓系白血病异基因造血细胞移植后的复发。

Br J Haematol. 2018 Feb;180(3):448-451. doi: 10.1111/bjh.14340. Epub 2016 Sep 21.

Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy.对于化疗分子反应不佳的初治完全缓解的inv(16)急性髓系白血病成年患者，异基因干细胞移植可能改善其预后。

Leuk Lymphoma. 2015;56(11):3116-23. doi: 10.3109/10428194.2015.1032964. Epub 2015 May 12.

The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.在 CBFB-MYH11 阳性急性髓系白血病患者中，两次巩固化疗后任何时间的微小残留病<0.1%的丢失或缺失预示着不良预后。

Br J Haematol. 2021 Jan;192(2):265-271. doi: 10.1111/bjh.16745. Epub 2020 Jun 25.

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.KIT突变与微小残留病联合对t(8;21)急性髓系白血病预后的影响。

Blood Cancer J. 2021 Apr 1;11(4):67. doi: 10.1038/s41408-021-00461-z.

Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.异基因骨髓或外周血祖细胞移植后inv(16)急性髓系白血病患者中CBFbeta/MYH11融合转录本的检测

Bone Marrow Transplant. 1998 Jan;21(2):159-66. doi: 10.1038/sj.bmt.1701056.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.诊断时WT1转录水平低预示着接受化疗或异基因造血干细胞移植的t(8;21)急性髓系白血病患者预后不良。

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.KIT 基因突变亚型和微小残留病灶均与核心结合因子急性髓系白血病的预后相关：单中心回顾性临床队列研究。

Ann Hematol. 2021 May;100(5):1203-1212. doi: 10.1007/s00277-021-04432-z. Epub 2021 Jan 20.

Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.D816V KIT 突变和移植前 CBFB-MYH11 MRD 监测对伴有 CBFB-MYH11 的急性髓系白血病的预后价值

Bone Marrow Transplant. 2021 Nov;56(11):2682-2689. doi: 10.1038/s41409-021-01384-w. Epub 2021 Jun 28.

Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.通过实时逆转录聚合酶链反应检测和定量inv(16)阳性急性髓性白血病患者中的CBFB/MYH11融合转录本

Genes Chromosomes Cancer. 2001 Apr;30(4):342-8. doi: 10.1002/gcc.1100.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.inv(16)/t(16;16) 伴非 A 型 CBFB-MYH11 融合的急性髓系白血病与独特的临床和遗传学特征相关，且缺乏 KIT 突变。

Blood. 2013 Jan 10;121(2):385-91. doi: 10.1182/blood-2012-07-442772. Epub 2012 Nov 16.

引用本文的文献

Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia.异基因移植前的疾病负担与移植后早期微小残留病相结合可预测急性髓系白血病患者的生存情况。

Ann Hematol. 2025 Apr;104(4):2469-2481. doi: 10.1007/s00277-025-06325-x. Epub 2025 Apr 25.

Single-cell immune landscape of measurable residual disease in acute myeloid leukemia.急性髓系白血病中可测量残留病的单细胞免疫景观。

Sci China Life Sci. 2024 Nov;67(11):2309-2322. doi: 10.1007/s11427-024-2666-8. Epub 2024 Jul 19.

[Chinese consensus on minimal residual disease detection and interpretation of patients with acute myeloid leukemia (2021)].《急性髓系白血病患者微小残留病检测与解读中国专家共识（2021年版）》

Zhonghua Xue Ye Xue Za Zhi. 2021 Nov 14;42(11):889-897. doi: 10.3760/cma.j.issn.0253-2727.2021.11.002.

How to Improve Prognostication in Acute Myeloid Leukemia with Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring.如何通过融合转录本改善急性髓系白血病的预后：聚焦分子可测量残留病（MRD）监测的作用

Biomedicines. 2021 Aug 3;9(8):953. doi: 10.3390/biomedicines9080953.

Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后结局的新型生物标志物。

Front Immunol. 2020 Aug 18;11:1854. doi: 10.3389/fimmu.2020.01854. eCollection 2020.

Strategies for minimal residual disease detection: current perspectives.微小残留病检测策略：当前观点

Blood Lymphat Cancer. 2019 Feb 12;9:1-8. doi: 10.2147/BLCTT.S172693. eCollection 2019.

Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.粒细胞集落刺激因子预处理的非血缘单倍体血液和骨髓移植。

Front Immunol. 2019 Nov 1;10:2516. doi: 10.3389/fimmu.2019.02516. eCollection 2019.

[Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].化疗联合供者淋巴细胞输注对异基因造血干细胞移植后微小残留病阳性患者慢性移植物抗宿主病及预后的影响

Zhonghua Xue Ye Xue Za Zhi. 2019 Sep 14;40(9):713-719. doi: 10.3760/cma.j.issn.0253-2727.2019.09.001.

[How I manage minimal residual disease positive patients with acute leukemia who underwent allogeneic stem cell transplantation].[我如何管理接受异基因干细胞移植的急性白血病微小残留病阳性患者]

Zhonghua Xue Ye Xue Za Zhi. 2018 Jun 14;39(6):448-453. doi: 10.3760/cma.j.issn.0253-2727.2018.06.002.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献